What Mifepristone Treats: Main Uses and Benefits

Mifepristone is used across domains where additional symptomatic support is needed in situations where patients experience noticeable physiological strain. The medication has two primary therapeutic applications concerning reproductive health and endocrine disease management.

Supportive Management for Endocrine Symptoms

This medication is applied in clinical settings that involve acute or unstable symptom patterns. It is relevant for easing symptom clusters related to systemic imbalance, such as hyperglycemia and hypertension in Endogenous Cushing's syndrome. Its use in these scenarios is considered relevant when supportive symptom management is appropriate, and it may assist with maintaining functional stability when symptoms are more noticeable.

Addressing Manifestations in Early Reproductive Contexts

The medication is commonly used to help with the medical termination of an early pregnancy, and it may be part of symptomatic management for early pregnancy loss. In these contexts, the drug supports patients during difficult episodes, which assists with maintaining functional stability during symptomatic phases.

---

Quick Fact: Relief for Metabolic Strain
This medication supports the management of high blood sugar and hypertension, which are symptoms linked to organ-specific functional stress in Cushing's syndrome.

Regulatory References

1. Mifepristone has two primary therapeutic applications

Eligibility Scope

The use of Mifepristone is determined by specific criteria outlined in official regulatory documents, defining both eligible and prohibited patient populations.

• Populations for whom use is allowed (as stated in label):
  • Adult Females for the medical termination of an intrauterine pregnancy up to 70 days of gestation (FDA) or 63 days of amenorrhea (EMA).
  • Adult Patients with endogenous Cushing’s syndrome and Type 2 Diabetes Mellitus or glucose intolerance who meet other labeled criteria.

---

Eligibility Classifications

Classification	Examples of Prohibited Conditions (Contraindications)
Absolute Contraindication	Chronic adrenal failure, Confirmed/suspected ectopic pregnancy, Inherited porphyria, Hemorrhagic disorders or concurrent anticoagulant therapy, or allergy to Mifepristone or Misoprostol.
Contextual Contraindication	Pregnancy when the medicine is used for Cushing's syndrome; having an Intrauterine Device (IUD) in place (must be removed).

---

Condition-Specific and Age-Related Rules

• Condition-Specific Rules: Patients with mild-to-moderate hepatic or renal impairment may require a dose restriction (up to 600 mg daily for Cushing's syndrome). Use is not recommended in cases of severe hepatic or renal failure for the termination indication due to lack of data.
• Age-Related Rules: Safety and effectiveness have not been established for use in pediatric and geriatric populations. The primary indication is restricted to females of childbearing age.
• Pregnancy/Lactation Status: The drug is indicated for pregnancy termination within the specified gestational limit but is contraindicated in pregnancy when used for Cushing’s syndrome. Breastfeeding should be avoided during long-term therapy.

---

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility by establishing absolute contraindications based on pre-existing health conditions (e.g., adrenal status and bleeding disorders) and strict limits related to the physiological state (e.g., gestational age). The label further structures eligibility through conditional use requirements for patients with impaired organ function and formal declarations that use is not established in certain age groups.

Interactions with other medicines and products

Mifepristone's interaction profile is characterized by its influence on metabolic enzymes and drug transporters, which can significantly alter the levels of co-administered medicines. The core interaction pattern involves the Cytochrome P450 (CYP) 3A enzyme system, where Mifepristone is documented as a potent inhibitor. This means that many drugs cleared by the CYP3A pathway may have their plasma concentrations increased when taken with Mifepristone.

Regulatory authorities have formally contraindicated the co-administration of Mifepristone with Strong CYP3A Substrates that have a narrow therapeutic range, such as Simvastatin, Lovastatin, Cyclosporine, Fentanyl, and Tacrolimus, due to the risk of dangerously increased exposure. Strong CYP3A Inducers, including Rifampicin and St. John's Wort, must also be avoided as they decrease Mifepristone's exposure, potentially reducing its effect.

Pharmacodynamic interactions are also documented. Due to Mifepristone's antiglucocorticoid activity, the therapeutic efficacy of long-term systemic corticosteroid therapy can be reduced for several days. Furthermore, concurrent use of Hormonal Contraceptives is restricted. For its approved regimens, Mifepristone requires the sequential administration of a prostaglandin analogue, a mandatory timing rule noted in the regulatory documents.

Mifepristone's mechanism of action is primarily defined by its role as a competitive antagonist at the progesterone receptor (PR). The drug exhibits high affinity for this receptor, which is densely expressed in the uterine lining, known as the decidua.

Upon binding to the PR, Mifepristone physically blocks endogenous progesterone from initiating its normal signaling cascade. This interruption prevents the progesterone-mediated gene transcription required to maintain the structural integrity and supportive state of the endometrium. The cessation of this signaling initiates a mechanistic cascade involving tissue degradation and vascular disruption.

This leads to the breakdown of the decidual tissue and vasoconstriction of the spiral arteries. Concurrently, the drug modulates the smooth muscle layer (myometrium) by inducing receptor upregulation, significantly increasing the density and affinity of prostaglandin receptors. This myometrial sensitization prepares the uterus for increased responsiveness to contractile stimuli, which is a key physiological effect required for the subsequent expulsion phase.

Mifepristone is administered exclusively by the oral route as a tablet, but the specific usage regimen is strictly determined by the medical context. The official instructions define two fundamentally different administration protocols.

For the medical termination indication, the drug is used as a single, non-repeating dose of 200 mg. This is the first step in a time-locked sequential regimen. Crucially, administration must take place in a supervised healthcare setting under the oversight of a certified provider. A follow-up examination is typically required 7 to 14 days after administration.

For the management of hyperglycemia in Cushing's syndrome, the regimen is once daily and is typically long-term. Treatment starts at 300 mg and is subject to gradual, upward titration, often in 300 mg increments, but no more frequently than every two to four weeks, up to a maximum daily dose of 1200 mg. This medication must be taken with a meal to ensure proper systemic delivery, and the tablet must be swallowed whole without alteration. Patients with moderate renal or hepatic impairment may be restricted to a lower maximum daily dose of 600 mg.

Research evidence / Overview of studies for Mifepristone

---

Evidence for Use in Medical Termination of Early Pregnancy

The research base for this context is extensive, primarily consisting of Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews and Meta-analyses. These studies were used in research exploring the combined use of the drug with a prostaglandin analog. Researchers examined outcomes related to complete expulsion without the need for additional procedures and monitored the rates of ongoing pregnancy. Study populations were generally adult women defined by specific gestational age criteria.

Findings describe patterns observed in these studies where the combination regimen was associated with measured rates of complete expulsion when compared to other methods. Research also highlights changes measured during the study period related to the time needed for the process to complete, with outcomes describing the pattern of expulsion. What remains uncertain is the need for more comparative research to explore all variables related to the regimen's component usage.

Evidence for Use in Cushing's Syndrome Management

Research has focused on managing metabolic symptoms linked to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Due to the rarity of this condition, the core evidence is derived from uncontrolled, open-label trials that included a limited number of participants.

Studies monitored physiological strain markers, specifically measuring changes in blood sugar control, blood pressure, and patient-reported functional status. Research highlights that measured changes were observed during the study period in metabolic markers in the observed populations. Observed patterns included descriptions of patient-reported changes and observed shifts in physical signs. The major research limitation is the small sample size of the trials.

---

Research in Specific Patient Groups and Gaps

For the pregnancy-related indications, studies have included adolescent populations and data show patterns related to outcomes that were evaluated relative to those observed in adults. For Cushing’s syndrome, the populations studied included patients with common co-morbidities like Type 2 Diabetes Mellitus.

Research is ongoing in several areas to fully contextualize the evidence landscape. The greatest uncertainty lies in the limited information for long-term outcomes and persistence of observed changes across all indications. Findings describe group patterns, but research does not determine whether an individual will respond similarly, and results apply only to the populations studied. Research is ongoing regarding how the regimen compares to other management options.

Common questions about Mifepristone (FAQ)

---

Q: What are the most common side effects of Mifepristone?

According to official product information, the most common side effects for the medical termination indication (affecting ge 1 in 10 patients) often include uterine contractions or cramping, gastrointestinal issues such as nausea, vomiting, or diarrhea, and headache. For patients taking the medication for Cushing's syndrome, common side effects may include nausea, vomiting, fatigue, headache, and decreased potassium levels (hypokalemia).

Q: What is the difference between the dose for medical termination and the dose for Cushing's syndrome?

Regulatory documents indicate that the administration regimens for the two indications are substantially different in dose structure and duration. For medical termination, the regimen involves a single administration as the initial step of a time-locked sequence. For Cushing's syndrome, the regimen is typically long-term, administered once daily, and is subject to gradual, upward dose adjustment over the course of treatment, starting at an initial prescribed dose.

Q: Can I use Mifepristone if I have severe kidney or liver problems?

Official information states that use of the medicine is generally not recommended for patients with severe hepatic impairment when managing Cushing's syndrome. For patients with mild to moderate kidney or liver impairment, official labeling indicates that a dose restriction or closer monitoring may be required. Use for the termination indication is generally not established in cases of severe renal or hepatic failure.

Q: What happens if I miss a dose of Mifepristone while taking it for Cushing’s syndrome?

Official prescribing information indicates that a missed dose should be taken as soon as it is remembered. However, if the next scheduled dose is approaching, the missed dose is usually skipped, and the patient should resume the regular schedule. Prescribing information also warns against taking a double dose to compensate for a missed one.

Q: What is the chemical structure of the active ingredient?

Regulatory information and public health databases describe the chemical structure of Mifepristone as a potent synthetic steroid compound. The official labeling specifies the chemical name and provides its empirical formula (C29H35NO2).

Q: How long will I be required to stay in the supervised healthcare setting after I take the tablet for a medical termination?

Official regulatory programs require that the initial dose of Mifepristone for medical termination must be administered in a supervised healthcare setting under a certified provider. However, the regulatory documentation does not specify a mandatory minimum duration of stay or observation time required immediately following the administration of the tablet.

Q: Is the tablet scored or can I split it to take a lower dose?

The official product labeling for the tablets used in Cushing's syndrome indicates they are not scored. The labeling advises that the tablet should be swallowed whole without alteration (splitting, crushing, or chewing) to ensure its proper delivery.

Storage and Disposal of Mifepristone Tablets

Official regulatory guidelines define specific conditions for storing and disposing of mifepristone to maintain its stability.

Storage/Disposal Constraint	Regulatory Requirement
Temperature Range	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C.
Environmental Protection	Tablets must be protected from light and stored away from excess heat and moisture. Keep from freezing.
Container & Safety	Keep the medicine in its original container and securely stored out of the sight and reach of children.
Disposal Instructions	Unused or expired medication must not be thrown away via wastewater or household trash. Dispose of the product according to local requirements for pharmaceutical waste.

These requirements ensure the product is stored within the stable temperature and light exposure constraints defined by the official labeling and is safely disposed of as pharmaceutical waste.